Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors

Liu, Lee Tai; Yuan, Ta-Tung; Liu, Hung-Huang; Chen, Shyh‐Fong; Wu, Ying‐Ta

doi:10.1016/j.bmcl.2007.08.061

Cited by 30 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The deprotection of the acetylene moiety of compound 12l by tetrabutylammonium fluoride (TBAF) led to anilinopyrrolo[1,2-a]quinoxaline 17 [39,40]. The palladium-catalyzed cross-coupling reaction of unprotected 3-ethynylaniline with 16 directly gave the Sonogashira side product 18 (Scheme 4).…”

Section: Chemistrymentioning

confidence: 99%

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2

Guillon¹,

Borgne²,

Rimbault³

et al. 2013

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tHerein we describe the synthesis and properties of substituted phenylaminopyrrolo[1,2-a]quinoxalinecarboxylic acid derivatives as a novel class of potent inhibitors of the human protein kinase CK2. A set of 15 compounds was designed and synthesized using convenient and straightforward synthesis protocols. The compounds were tested for inhibition of human protein kinase CK2, which is a potential drug target for many diseases including inflammatory disorders and cancer. New inhibitors with IC 50 in the microand sub-micromolar range were identified. The most promising compound, the 4-[(3-chlorophenyl) amino]pyrrolo[1,2-a]quinoxaline-3-carboxylic acid 1c inhibited human CK2 with an IC 50 of 49 nM. Our findings indicate that pyrrolo[1,2-a]quinoxalines are a promising starting scaffold for further development and optimization of human protein kinase CK2 inhibitors.

show abstract

Section: Chemistrymentioning

confidence: 99%

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2

Guillon¹,

Borgne²,

Rimbault³

et al. 2013

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…Although mesh nebulizers are capable of nebulizing most drug formulations on the market today, the viscosity and surface tension of the formulation can affect output rate. Mesh nebulizers can typically deliver formulations of surface tension in the range 35-75 mN/m with a range of viscosities ( Figure 1) [22], although the range is not as wide as for jet nebulizers (1-6 Cp) [23].…”

Section: New Nebulizer Technologymentioning

confidence: 99%

“…In this study, a total of 109 EGFR (T790M) and 90 cMET inhibitors were obtained from the literature comprising diverse series of compounds [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]. Focus was laid on the fact that all the compounds followed the same mechanism of action and employed similar experimental procedures for calculating biological activity.…”

Section: Datasetmentioning

confidence: 99%

Nebulized Drug Delivery in Respiratory Medicine: What Does the Future Hold?

Pritchard

2017

Ther. Deliv.

View full text Add to dashboard Cite

In the later half of the 20th century, nebulized therapy was in decline, but in the 21st century the prospects for the expanded use of nebulized therapy within respiratory medicine look bright. The advent of mesh nebulizers, which combine the universal applicability of the nebulizer in the treatment of all respiratory patients with the convenience of portable inhaler use, is ideally timed to capitalize on the forecast of increased numbers of patients who will require nebulized therapy in the future. This special report will highlight some of the opportunities that the development of mesh nebulizers presents in the field of respiratory medicine.

show abstract

“…In the course of finding novel chemical agents that may serve as innovative antitumor agents, quinazoline derivatives are of particular interest [5]. In the last few years, the thieno [2,3-d]pyrimidine core was evaluated as bioisostere of 4-anilinoquinazoline core which included potent marketed anticancer drugs like Gefitinib (Iressa TM ) [6], Erlotinib (Tarceva TM ) [7] and Tandutinib (MLN518) (phase II clinical trials) [8].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Antitumor Activity of Novel Thienopyrimidine Derivatives Containing Thiosemicarbazide Moiety

Salib¹,

Khalil²,

Kamel³

et al. 2016

OALib

View full text Add to dashboard Cite

The present study focused on synthesizing a series of novel derivatives of 4-aryl-1-[2-(3-benzyl-4oxo(3H)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-2-ylsulphanyl) acetyl] thiosemicarbazide 5a-d and evaluating their antitumor activity. The structure of the synthesized compounds has been elucidated on the basis of elemental analyses and spectroscopic methods (IR, 1 H-NMR, 13 C-NMR and MS). The in vitro cytotoxic activity of the synthesized derivatives was evaluated against two human cell lines: prostate cancer (PC-3) and colon cancer (HCT-116).

show abstract

Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors

Cited by 30 publications

References 18 publications

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2

Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2

Nebulized Drug Delivery in Respiratory Medicine: What Does the Future Hold?

Synthesis and Antitumor Activity of Novel Thienopyrimidine Derivatives Containing Thiosemicarbazide Moiety

Contact Info

Product

Resources

About